Ohr Pharmaceutical, Inc.
Period Ending Sep 30, 2013 Sep 30, 2012 Sep 30, 2011 Sep 30, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 2,610 1,626 522 303
Sales, General and Admin. 2,011 1,661 721 713
Non-Recurring Items - - - -
Other - - - -
Operating Income (4,621) (3,286) (1,243) (1,016)
Income From Continuing Operations
Add'l Income/Expense Items (1,027) 1,833 (3,856) 1,531
Earnings Before Interest and Tax (5,648) (1,453) (5,099) 516
Interest Expense 5 2 2 21
Earnings Before Tax (5,652) (1,455) (5,102) 494
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,652) (1,455) (5,102) 494
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,652) (1,455) (5,102) 494
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,652) (1,455) (5,102) 494